PLUS THERAPEUTICS Inc. (PSTV) Financial Statements (2024 and earlier)

Company Profile

Business Address 4200 MARATHON BLVD.
AUSTIN, TX 78756
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,554,00011,006,00010,895,00012,723,00018,120,00020,266,000
Cash and cash equivalents8,554,00011,006,00010,895,00012,723,00018,120,00020,266,000
Short-term investments      
Receivables  91,000718,000  73,000
Other current assets1,280,000487,000751,000906,0003,697,000540,000
Total current assets:9,834,00011,584,00012,364,00013,629,00021,817,00020,879,000
Noncurrent Assets
Operating lease, right-of-use asset202,000232,000242,000270,000248,000275,000
Property, plant and equipment906,0001,009,0001,143,0001,276,0001,324,0001,453,000
Intangible assets, net (including goodwill)414,000421,000436,000451,000466,000485,000
Goodwill372,000372,000372,000372,000372,000372,000
Intangible assets, net (excluding goodwill)42,00049,00064,00079,00094,000113,000
Other noncurrent assets32,00032,00012,00012,00012,00012,000
Total noncurrent assets:1,554,0001,694,0001,833,0002,009,0002,050,0002,225,000
TOTAL ASSETS:11,388,00013,278,00014,197,00015,638,00023,867,00023,104,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6,631,0006,073,0006,580,0006,495,00010,134,0005,705,000
Accounts payable 4,758,000   8,364,000 
Accrued liabilities 1,115,000   1,136,000 
Other undisclosed accounts payable and accrued liabilities758,0006,073,0006,580,0006,495,000634,0005,705,000
Deferred revenue   1,137,000  
Debt3,976,0004,348,0004,709,0005,057,0001,608,0001,608,000
Other undisclosed current liabilities120,000117,000110,000107,000110,000107,000
Total current liabilities:10,727,00010,538,00011,399,00012,796,00011,852,0007,420,000
Noncurrent Liabilities
Long-term debt and lease obligation     3,786,0004,280,000
Long-term debt, excluding current maturities     3,786,0004,108,000
Liabilities, other than long-term debt2,009,000118,000136,000166,0001,784,000 
Deferred revenue 1,924,000   1,643,000 
Operating lease, liability85,000118,000136,000166,000141,000172,000
Other undisclosed noncurrent liabilities      (172,000)
Total noncurrent liabilities:2,009,000118,000136,000166,0005,570,0004,280,000
Total liabilities:12,736,00010,656,00011,535,00012,962,00017,422,00011,700,000
Equity
Equity, attributable to parent(1,348,000)2,622,0002,662,0002,676,0006,445,00011,404,000
Common stock5,0005,0003,00036,00034,00032,000
Treasury stock, value(126,000)     
Additional paid in capital479,274,000479,308,000476,131,000474,630,000473,596,000472,899,000
Accumulated deficit(480,501,000)(476,691,000)(473,472,000)(471,990,000)(467,185,000)(461,527,000)
Total equity:(1,348,000)2,622,0002,662,0002,676,0006,445,00011,404,000
TOTAL LIABILITIES AND EQUITY:11,388,00013,278,00014,197,00015,638,00023,867,00023,104,000

Income Statement (P&L) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Operating expenses(5,173,000)(4,491,000)(3,344,000)(5,226,000)(5,723,000)(5,167,000)
Other undisclosed operating income1,313,0001,240,0001,854,000506,000151,00073,000
Operating loss:(3,860,000)(3,251,000)(1,490,000)(4,720,000)(5,572,000)(5,094,000)
Nonoperating income (expense)50,00032,0008,000(85,000)(86,000)(125,000)
Investment income, nonoperating110,000119,000120,00051,00073,00048,000
Interest and debt expense(62,000)(87,000)(112,000)(134,000)(159,000)(173,000)
Loss from continuing operations:(3,872,000)(3,306,000)(1,594,000)(4,939,000)(5,817,000)(5,392,000)
Loss before gain (loss) on sale of properties:(5,392,000)
Net loss:(3,872,000)(3,306,000)(1,594,000)(4,939,000)(5,817,000)(5,392,000)
Other undisclosed net income attributable to parent62,00087,000112,000134,000159,000173,000
Net loss available to common stockholders, diluted:(3,810,000)(3,219,000)(1,482,000)(4,805,000)(5,658,000)(5,219,000)

Comprehensive Income (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(3,872,000)(3,306,000)(1,594,000)(4,939,000)(5,817,000)(5,392,000)
Comprehensive loss, net of tax, attributable to parent:(3,872,000)(3,306,000)(1,594,000)(4,939,000)(5,817,000)(5,392,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: